Cargando…

Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria

We sought to determine the prevalence of probable disseminated histoplasmosis among advanced HIV disease (AHD) patients in Nigeria. We conducted a cross-sectional study in 10 sites across 5 of 6 geopolitical zones in Nigeria. We identified patients with urinary samples containing CD4 cell counts <...

Descripción completa

Detalles Bibliográficos
Autores principales: Oladele, Rita O., Osaigbovo, Iriagbonse I., Akanmu, Alani S., Adekanmbi, Olukemi A., Ekeng, Bassey E., Mohammed, Yahaya, Alex-Wele, Mary A., Okolo, Mark O., Ayanbeku, Stephen T., Unigwe, Uchechukwu S., Akase, Iorhen E., Dan-Jumbo, Alali, Isralski, Dennis, Denning, David W., Pasqualotto, Alessandro C., Chiller, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622240/
https://www.ncbi.nlm.nih.gov/pubmed/36286009
http://dx.doi.org/10.3201/eid2811.220542
_version_ 1784821717644869632
author Oladele, Rita O.
Osaigbovo, Iriagbonse I.
Akanmu, Alani S.
Adekanmbi, Olukemi A.
Ekeng, Bassey E.
Mohammed, Yahaya
Alex-Wele, Mary A.
Okolo, Mark O.
Ayanbeku, Stephen T.
Unigwe, Uchechukwu S.
Akase, Iorhen E.
Dan-Jumbo, Alali
Isralski, Dennis
Denning, David W.
Pasqualotto, Alessandro C.
Chiller, Tom
author_facet Oladele, Rita O.
Osaigbovo, Iriagbonse I.
Akanmu, Alani S.
Adekanmbi, Olukemi A.
Ekeng, Bassey E.
Mohammed, Yahaya
Alex-Wele, Mary A.
Okolo, Mark O.
Ayanbeku, Stephen T.
Unigwe, Uchechukwu S.
Akase, Iorhen E.
Dan-Jumbo, Alali
Isralski, Dennis
Denning, David W.
Pasqualotto, Alessandro C.
Chiller, Tom
author_sort Oladele, Rita O.
collection PubMed
description We sought to determine the prevalence of probable disseminated histoplasmosis among advanced HIV disease (AHD) patients in Nigeria. We conducted a cross-sectional study in 10 sites across 5 of 6 geopolitical zones in Nigeria. We identified patients with urinary samples containing CD4 cell counts <200 cells/mm(3) or World Health Organization stage 3 or 4 disease who also had >2 clinical features of disseminated histoplasmosis, and we tested them for Histoplasma antigen using a Histoplasma enzyme immune assay. Of 988 participants we recruited, 76 (7.7%) were antigen-positive. The 76 Histoplasma antigen–positive participants had significantly lower (p = 0.03) CD4 counts; 9 (11.8%) were also co-infected with tuberculosis. Most antigen-positive participants (50/76; 65.8%; p = 0.015) had previously received antiretroviral treatment; 26/76 (34.2%) had not. Because histoplasmosis is often a hidden disease among AHD patients in Nigeria, Histoplasma antigen testing should be required in the AHD package of care.
format Online
Article
Text
id pubmed-9622240
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-96222402022-11-05 Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria Oladele, Rita O. Osaigbovo, Iriagbonse I. Akanmu, Alani S. Adekanmbi, Olukemi A. Ekeng, Bassey E. Mohammed, Yahaya Alex-Wele, Mary A. Okolo, Mark O. Ayanbeku, Stephen T. Unigwe, Uchechukwu S. Akase, Iorhen E. Dan-Jumbo, Alali Isralski, Dennis Denning, David W. Pasqualotto, Alessandro C. Chiller, Tom Emerg Infect Dis Research We sought to determine the prevalence of probable disseminated histoplasmosis among advanced HIV disease (AHD) patients in Nigeria. We conducted a cross-sectional study in 10 sites across 5 of 6 geopolitical zones in Nigeria. We identified patients with urinary samples containing CD4 cell counts <200 cells/mm(3) or World Health Organization stage 3 or 4 disease who also had >2 clinical features of disseminated histoplasmosis, and we tested them for Histoplasma antigen using a Histoplasma enzyme immune assay. Of 988 participants we recruited, 76 (7.7%) were antigen-positive. The 76 Histoplasma antigen–positive participants had significantly lower (p = 0.03) CD4 counts; 9 (11.8%) were also co-infected with tuberculosis. Most antigen-positive participants (50/76; 65.8%; p = 0.015) had previously received antiretroviral treatment; 26/76 (34.2%) had not. Because histoplasmosis is often a hidden disease among AHD patients in Nigeria, Histoplasma antigen testing should be required in the AHD package of care. Centers for Disease Control and Prevention 2022-11 /pmc/articles/PMC9622240/ /pubmed/36286009 http://dx.doi.org/10.3201/eid2811.220542 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Oladele, Rita O.
Osaigbovo, Iriagbonse I.
Akanmu, Alani S.
Adekanmbi, Olukemi A.
Ekeng, Bassey E.
Mohammed, Yahaya
Alex-Wele, Mary A.
Okolo, Mark O.
Ayanbeku, Stephen T.
Unigwe, Uchechukwu S.
Akase, Iorhen E.
Dan-Jumbo, Alali
Isralski, Dennis
Denning, David W.
Pasqualotto, Alessandro C.
Chiller, Tom
Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria
title Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria
title_full Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria
title_fullStr Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria
title_full_unstemmed Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria
title_short Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria
title_sort prevalence of histoplasmosis among persons with advanced hiv disease, nigeria
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622240/
https://www.ncbi.nlm.nih.gov/pubmed/36286009
http://dx.doi.org/10.3201/eid2811.220542
work_keys_str_mv AT oladeleritao prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT osaigbovoiriagbonsei prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT akanmualanis prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT adekanmbiolukemia prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT ekengbasseye prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT mohammedyahaya prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT alexwelemarya prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT okolomarko prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT ayanbekustephent prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT unigweuchechukwus prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT akaseiorhene prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT danjumboalali prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT isralskidennis prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT denningdavidw prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT pasqualottoalessandroc prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria
AT chillertom prevalenceofhistoplasmosisamongpersonswithadvancedhivdiseasenigeria